Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Incyte's Marketable Securities for the quarter that ended in Jun. 2026 was MXN9,656 Mil.
Incyte's annual Marketable Securities
increased
from Dec. 2023 (MXN7,514 Mil) to Dec. 2024 (MXN9,808 Mil) but then
declined
from Dec. 2024 (MXN9,808 Mil) to Dec. 2025 (MXN8,693 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Incyte Marketable Securities Related Terms
Incyte Marketable Securities Historical Data
* Premium members only.
The historical data trend for Incyte's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of MXN9,656 Mil mean?
Incyte (MEX:INCY) has a Marketable Securities of MXN9,656 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Incyte and its competitors.
Is Incyte's Marketable Securities too high?
Incyte's current Marketable Securities is MXN9,656 Mil. Overall, Incyte has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Marketable Securities compare to INSM and BNTX?
Incyte's Marketable Securities of MXN9,656 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Incyte and its competitors. Incyte's current Marketable Securities is MXN9,656 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,739.76, compared to a current price of MXN2,036.00 — trading 17% above its estimated fair value. The current Marketable Securities is MXN9,656 Mil. Incyte's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Marketable Securities is MXN9,656 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN2,036.00 is trading 17% above its estimated GF Value™ of MXN1,739.76.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
Marketable Securities: MXN9,656 Mil
GF Value™: MXN1,739.76 vs. price of MXN2,036.00 (17% above fair value)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
83GF Score
Get the complete analysis for MEX:INCY
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
